Dear Editor,
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I was pleased to see more data generated from the EPIC (evaluation of pimobendan in dogs with cardiomegaly caused by preclinical myxomatous mitral valve disease) trial (see "Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study" *J Vet Intern Med*. 2020 Mar 22. doi: [10.1111/jvim.15753](https://doi.org/10.1111/jvim.15753)). As a comment, I have a slightly different interpretation of the data regarding resting respiratory rate (RRR) in this paper. The investigators in this study based on the diagnosis of left heart failure (pulmonary edema) on clinical and radiographic signs at the time a dog was presented by the owner to the investigator. This means clinical signs had to be severe enough for the owner to notice them and pulmonary edema had to be severe enough to be apparent radiographically. In figure 3D, if one makes the logical assumption that the increase in RRR was caused by pulmonary edema, it seems clear to me that the dogs that were subsequently diagnosed with left heart failure had mild pulmonary edema for several weeks before their tachypnea and dyspnea becoming severe enough for the owner to notice a problem. Since I was the first to start by RRR and sleeping RR (SRR) in 1998 I may be biased, but I believe these data clearly show that RRR/SRR is a more sensitive means of identifying pulmonary edema (left heart failure), presumably mild edema, in dogs with severe mitral regurgitation than are thoracic radiographs and clinical signs, such as tachypnea and dyspnea, that are severe enough to be apparent to an owner. As such, in my opinion, an elevated RRR is not evidence of impending or incipient left heart failure but instead is the first clinical evidence that a dog is in left heart failure.
